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Identity 
Hugo: SPINK7 
Other names: ECRG2; ECG2; MGC133105; 
MGC133106 
Location: 5q33.1 
Local order: Telomeric to SPINK5L3 and centromeric 
to SPINK1. 
DNA/RNA 
 
 
Diagram of ECRG2 gene. Exons are represented by red 
boxes. Exons 1 to 4 from 5' to 3' direction. 
Description 
The ECRG2 gene contains 4 exons and spans about 
3540 bp. 
Transcription 
The full-length of cDNA of ECRG2 gene was revealed 
569 bp, the open reading frame (ORF) is 258 bp. The 
sequence upstream of the exon-1 upon the 
NT_2023158.1 genomic sequence revealed a typical 
TATA box contained promotor at 44 bp from the 
predicted translation start site. The transcription start 
site is just 6 bp upstream of the 5' end sequence. 
Pseudogene 
None. 
 
 
Protein 
Note: The N-terminal 1-19 is the single peptide of the 
protein. The C-terminal 30-85 of the protein contains a 
typical x(8)-C-x(6)-C-x(7)-C-x(6)-Y-x(3)-C-x(2,3)-C-
x(17)-C conserve region, coding a Kazal type serine 
protease inhibitors (Kazal) domain. 
 
Description 
The molecular weight of the encoding protein 
contained 85 amino acids is about 9.23 kDa. ECRG2 
gene contains a typical Kazal serine protease inhibitors 
conserved domain about 56 amino acids at its C-
terminal and three kinase phosphorlation site (protein 
kinase C, Casein kinase II and Tyrosine kinase). 
Expression 
ECRG2 gene was expressed in normal tissues, such as 
esophagus, liver, colon and lung. But it was less 
expressed in the cancerous tissues, especially low 
frequency of expression of ECRG2 gene in esophageal 
cancer but was less expressed in the cancerous tissues, 
especially low frequency of expression of ECRG2 gene 
in esophageal cancer. 
Localisation 
The protein was localized on the cell membrane. 
Function 
The expression of ECRG2 can inhibit the migratory 
ability of high metastasic tumor cells. 
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Homology 
The sequence of the ECRG2 gene did not reveal 
remarkable similarity to the known sequence in the 
homology analysis with the public database of 
GenBank while the deduced amino acid sequence 
showed 97% homology to a tumor associated KAZAL-
type serine protease inhibitor peptide (US patent 
5851987). 
Mutations 
Note: None 
Implicated in 
Esophageal cancer 
Note: Expression profile of ECRG2 gene in 7 normal 
esophageal epithelia, 51 esophageal cancers and 33 
tumor adjacent tissues were 100%, 21% and 52% 
respectively. About 79% of ECRG2 gene was no 
expressed in the esophageal cancer. ECRG2 was highly 
expressed in the adult normal esophageal tissue, low 
expressed in the fetal esophageal tissue and completely 
loss of expression in the esophageal cancer and 
corresponding adjacent tissues. The results show that 
the ECRG2 gene may be a specific gene for 
carcinogenesis of esophagus. 
The studies provide more evidences on the role of 
ECRG2 in the inhibition of tumor cell proliferation, 
migration and metastasis, and give a straightforward 
way to block enzymatic activity in extra-cellular matrix 
to achieve the therapeutic benefit in the tested human 
cancers. 
1. Short tandem repeat polymorphism in a novel 
esophageal cancer-related gene (ECRG2) implicates 
susceptibility to esophageal cancer  
2. Potential interaction partner for ECRG2 might be 
involved in regulation of cell proliferation and  
apoptosis and in various physiological processes. 
3. Data suggest that the physical interaction of 
esophageal cancer related gene 2 (ECRG2) and 
metallothionein2A (MT2A) may play an important role 
in the carcinogenesis of esophageal cancer. 
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